Trial Profile
USE OF SORAFENIB IN THE PREVENTION OF RELAPSE OF RESECTED/ABLATED HEPATOCELLULAR CARCINOMA (HCC) IN PATIENTS WITH HEPATITIS C VIRUS CHRONIC INFECTION.
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 23 Oct 2012
Price :
$35
*
At a glance
- Drugs Sorafenib (Primary)
- Indications Liver cancer
- Focus Therapeutic Use
- 23 Oct 2012 New trial record